Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.
NCT03388853
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
COPD
Interventions
DRUG:
Acetylcysteine/Doxofylline
OTHER:
Placebo
Sponsor
Neutec Ar-Ge San ve Tic A.Ş